|
News Release
Imaging3 Files with Federal Drug Administration
510(k) Application Filed with FDA on June 15, 2007
Burbank, CA – June 19, 2007 – Imaging3™, Inc., (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that the company has filed it’s 510(k) submission for the DominionTM 3D real-time imaging device with the FDA on June 15th as promised.
“I’m pleased to announce that Imaging3 has met its filing deadline for submission of the Dominion real-time imaging device to the FDA for their approval,” stated Mr. Dean Janes Chairman and CEO of Imaging3. Mr. Janes added “this critical milestone represents the start of a new phase in Dominion development and brings us one important step closer to delivering this breakthrough technology to the healthcare marketplace”.
Mr. Janes noted that this will be the fourth Fluoroscopy based imaging device that he has personally navigated through the 510(k) submission process. “Based on our previous experience we believe that we have a good understanding of what the FDA needs to see in the submission and we have kept those needs at the forefront throughout the Dominion’s development,” added Mr. Janes. “While there are no guarantees on how long this process can take, we have done everything in our power to deliver as much data as possible,” Mr. Janes concluded.
About Imaging3, Inc.
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough technology (patented) that will produce 3D medical diagnostic images in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body.
Imaging3 Technology can to contribute to the improvement of healthcare. By providing this higher quality and quantity of information, the physician or clinician will be able to perform any procedure with a higher level of accuracy while decreasing the time spent performing the procedure. By increasing throughput while increasing diagnostic and clinical accuracy, Imaging3 Technology becomes an attractive new technology that will provide healthcare centers with a high return on investment.
For more information about Imaging3, Inc., please visit the Company's Web site
www.Imaging3.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Contact:
Imaging3, Inc.
Media Relations
(818) 260-0930
|
|
